: Thymic and bone marrow outputs were evaluated in 13 sequential samples of 68 multiple sclerosis patients who initiated alemtuzumab and were clinically followed for 48 months. Three months after alemtuzumab infusions, the levels of new T lymphocytes were significantly reduced, but progressively increased reaching the highest values at 36 months, indicating the remarkable capacity of thymic function recovery. Newly produced B cells exceeded baseline levels as early as 3 months after alemtuzumab initiation. Heterogeneous patterns of new T- and B-cell recovery were identified, but without associations with age, sex, previous therapies, development of secondary autoimmunity or infections, and disease re-emergence. Trial registration version 2.0-27/01/2016.
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab / Sottini, Alessandra; Quaresima, Virginia; Barbaro, Mosè; Moiola, Lucia; Filippi, Massimo; Malentacchi, Maria; Capobianco, Marco; Puthenparampil, Marco; Gallo, Paolo; Cocco, Eleonora; Frau, Jessica; Zaffaroni, Mauro; Guaschino, Clara; Stampatori, Chiara; Mancinelli, Chiara; Brambilla, Laura; Clerici, Valentina Torri; Vianello, Marika; Vitetta, Francesca; Ferraro, Diana; Rosettani, Pamela; Danni, Maura Chiara; Conti, Marta; Grimoldi, Maria; Capra, Ruggero; Imberti, Luisa. - In: JOURNAL OF NEUROIMMUNOLOGY. - ISSN 0165-5728. - 382:(2023). [10.1016/j.jneuroim.2023.578170]
Clinical relevance of thymic and bone marrow outputs in multiple sclerosis patients treated with alemtuzumab
Filippi, Massimo;
2023-01-01
Abstract
: Thymic and bone marrow outputs were evaluated in 13 sequential samples of 68 multiple sclerosis patients who initiated alemtuzumab and were clinically followed for 48 months. Three months after alemtuzumab infusions, the levels of new T lymphocytes were significantly reduced, but progressively increased reaching the highest values at 36 months, indicating the remarkable capacity of thymic function recovery. Newly produced B cells exceeded baseline levels as early as 3 months after alemtuzumab initiation. Heterogeneous patterns of new T- and B-cell recovery were identified, but without associations with age, sex, previous therapies, development of secondary autoimmunity or infections, and disease re-emergence. Trial registration version 2.0-27/01/2016.| File | Dimensione | Formato | |
|---|---|---|---|
|
J Neuroimmunol 382_578170.pdf
accesso aperto
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Creative commons
Dimensione
2.75 MB
Formato
Adobe PDF
|
2.75 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
